Day

November 19, 2013

BOTHELL, WA–(Marketwired – Nov 18, 2013) – Borneo Resource Investments Ltd. (OTCQB: BRNE), (the “Company” or “Borneo”) a developer of thermal coal concessions and producing gold properties in Indonesia, today announced financial results for the three and nine months ended September 30, 2013.

Highlights include:

$507,771 in revenues in Q3 2013, compared to zero revenues in the same period of 2012 and $212,639 in Q2 2013
$41,201 in net income attributable to Borneo shareholders in Q3 2013, compared to no net income in the same period of 2012 and a net loss in Q2 2013
Q3 2013 marks first full quarter of gold mining at Talawaan Property
Conducted research and feasibility on gold mining at Ratatotok Property
Actively pursued coal concessions as part of Company’s long term strategy
“Producing revenues and profits, Borneo reached an important milestone this quarter. Our financial results provide early validation of our strategy. The value matrix for Borneo is clear. Cash flow producing investments in gold properties will help fund our operations, and build and preserve shareholder value for Borneo, while we pursue longer term, high value investments in high quality thermal coal concessions,” commented Borneo CEO Nils Ollquist.

“Having just completed the acquisition of PT Puncak Kalabat in June of 2013, we swiftly started gold production at the Talawaan Property. We believe we can significantly increase production at Talawaan, as well as begin production at Ratatotok in the coming quarters. Further, the acquisition of Kalabat is proving to be a platform through which we are exploring additional opportunities to expand our precious metals project portfolio, as well as coal concessions,” Ollquist added.

In the three months ended September 30, 2013, Borneo reported revenues of $507,771 from gold production at its Talawaan Property, a 50 hectare property located in the Manado region of Indonesia. Costs applicable to sales were $215,592 for labor and other costs incurred in mining and processing gold. The Company reported zero revenues and zero costs applicable to sales in the third quarter of 2012. Net income attributable to Borneo shareholders was $41,201 or $0.00 per basic and diluted common share for the third quarter of 2013, compared to a net loss attributable to Borneo shareholders of $(265,625) or $(0.00) per basic and diluted common share in the same period of the prior year.

For the nine month period ended September 30, 2013, Borneo reported revenues of $720,410 from gold production at its Talawaan Property. Costs applicable to sales were $310,263 for labor and other costs incurred in mining and processing gold. The Company reported zero revenues and zero costs applicable to sales in the first three quarters of 2012. Net loss attributable to Borneo shareholders was $(246,771), or $(0.00) per basic and diluted common share in the first nine months of 2013 as compared to $(1,658,510) or $(0.02) per basic and diluted common share in the same period of the prior year.

About The Company

Borneo Resource Investments Ltd. is an aggregator of proven precious metal and natural resource concession assets in the Republic of Indonesia. Each concession is a contractual right to explore or develop natural resources in a specific land area. Borneo’s current natural resource portfolio includes two gold projects and a concession for high quality thermal coal. The first gold project is producing while the other is non-producing. Borneo also trades precious metals and thermal coal between Indonesian domestic groups and international buyers. Borneo seeks to opportunistically acquire and market additional natural resource assets.

WILMINGTON, Mass., Nov. 18, 2013 /PRNewswire/ — Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it has sold its QS-B220 desktop explosives trace detector to a leading regional US airline with growing air cargo revenues. The seven units will be deployed across five locations in the airline’s network.

“The customer was impressed with the QS-B220’s ease of use, non-radioactive source, push-button maintenance, and its low cost of ownership,” stated Implant Sciences’ Vice President of Sales and Marketing, Dr. Darryl Jones. “Buyer after buyer is telling us that the value proposition offered by Implant Sciences is far superior to anything else they’ve seen.”

“As a leading airline that also conducts its own baggage screening, the purchase decision makers at this airline are extremely experienced and knowledgeable about air cargo screening. It was a pleasure working with them, and we look forward to a long-term customer relationship with them,” stated Glenn D. Bolduc, President and CEO of Implant Sciences.

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than competing products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. The Company is the third ETD manufacturer, and the sole American-owned company, to currently have product qualification from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. In addition to being named a Qualified Product by TSA on the Air Cargo Screening Technology List, the QS-B220 has received certification from STAC in France, and Designation as a Qualified Anti-Terrorism Technology by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). Implant Sciences’ QS-H150 handheld explosives trace detector is also a Designated Qualified Anti-Terrorism Technology under the SAFETY Act. For further details on the Company and its products, please visit the Company’s website at www.implantsciences.com.

JERUSALEM, Nov. 19, 2013 /PRNewswire/ — Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today that the European Patent Office has allowed the Company’s patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins.”

Europe is one of the world’s largest healthcare markets with an estimated $322 billion market value in 2012, accounting for over one quarter of the world pharmaceutical market, according to a report by the European Federation of Pharmaceutical Industries and Associations. According to Frost & Sullivan the European diabetes market accounted for $8.6 billion in revenues in 2010 and is estimated to grow to $14 billion by 2017, driven by new classes of drugs to treat the disease.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top research scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), with trials on healthy volunteers (Phase 1b) and T2DM patients (Phase 2a) underway. Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The company’s corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit http://www.oramed.com